Dr. Reddy’s Laboratories has issued a statement acknowledging that it has received a Warning Letter issued by the US Food and Drug Administration dated November 05, 2015 relating to its active pharmaceutical ingredient (API) manufacturing facilities in India at Srikakulam, Andhra Pradesh and Miryalaguda, Telangana, as well as for an oncology formulation manufacturing facility at Duvvada, Visakhapatnam, Andhra Pradesh, India. This action follows the earlier inspections of these sites by the agency in November 2014, January 2015, and February 2015, respectively.

Dr. Reddy's Chief Executive Officer G. V. Prasad commented in a company statement. “We take quality and compliance matters seriously and stand by our commitment to fully comply with the cGMP quality standards across all of our facilities. We will respond with a comprehensive plan to address these observations within the stipulated time-frame of 15 days. We will continue to actively engage with the agency to resolve these issues and we have also embarked on an initiative to revamp our quality systems and processes, as an organization-wide priority.”

Source: Dr. Reddy’s Laboratories